SBIR/STTR Research Award

Efficient Synthesis of (+)-Discodermolide

Award identifier 138c898aa83d740cad3ad33a978f96b895272220f3c48860cece0b7537d390fdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Kosan Biosciences, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The long term objective of this proposal is to develop an efficient, economical means of producing the polyketide (+)-discodermolide. This compound shows promising anticancer activity, having a similar mode of action as paclitaxel and epothilone, but is available only in minute quantity from its natural source, the deep-water marine sponge Discodermia dissolute. Total synthesis is the only option at present for producing sufficient quantities for clinical testing. Several total syntheses have been reported, yet all are lengthly and expensive. The most concise synthesis to date (Smith et al.) divides discodermolide into three segments. Each segment is elaborated from a common precursor, itself prepared via a multi-step route using expensive reagents. The PI proposes to develop a process to prepare an equivalent of this common precursor by fermentation, using genetically engineered polyketide synthases. In Phase 1, we will develop the methods to prepare this material and demonstrate its utility by conversion to the Smith common precursor. In Phase 2, we will develop the methodology to incorporate our fermentation product directly into the synthesis of (+)-discodermolide. The researchers will also explore the use of other natural polyketides as more advanced synthetic intermediates to decrease the number of steps required to produce discodermolide. The PI anticipates that this use of engineered enzymes will dramatically reduce the cost of preparing (+)-discodermolide, and facilitate the commercial development of this anticancer agent. PROPOSED COMMERCIAL APPLICATION: Discodermolide is a potential successor to paclitaxel (Taxol). The current market for paclitaxel is quite large, yet there are many problems associated with this drug. Discodermolide has many favorable aspects, including greater water solubility and activity against Taxol-resistance cells, and so could take over a large portion of the Taxol market. The present proposal should overcome the supply problem of discodermolide, thus facilitating it commercial development.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.